Search

Your search keyword '"Didier Hannequin"' showing total 336 results

Search Constraints

Start Over You searched for: Author "Didier Hannequin" Remove constraint Author: "Didier Hannequin"
336 results on '"Didier Hannequin"'

Search Results

1. Phenotype and imaging features associated with APP duplications

2. Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies

3. How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

4. APP, PSEN1, and PSEN2 mutations in early-onset Alzheimer disease: A genetic screening study of familial and sporadic cases.

5. An Autopsy Case of Amyotrophic Lateral Sclerosis with Waldenström Macroglobulinemia and Anti-MAG Gammopathy

6. Deletion of the progranulin gene in patients with frontotemporal lobar degeneration or Parkinson disease

7. Association study of the GAB2 gene with the risk of developing Alzheimer's disease

8. Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease.

9. Visual agnosia and posterior cerebral artery infarcts: an anatomical-clinical study.

10. New insights into the genetic etiology of Alzheimer's disease and related dementias

11. A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

12. Recurrence of an early postzygotic rescue of an inherited unbalanced translocation resulting in mosaic segmental uniparental isodisomy of chromosome 11q in siblings

13. Penetrance estimation of Alzheimer disease in SORL1 loss-of-function variant carriers using a family-based strategy and stratification by APOE genotypes

15. SLITRK2, an X-linked modifier of the age at onset in C9orf72 frontotemporal lobar degeneration

16. Effect of the Histone Deacetylase Inhibitor FRM-0334 on Progranulin Levels in Patients With Progranulin Gene Haploinsufficiency: A Randomized Clinical Trial

17. Clinical and neuropathological diversity of tauopathy in MAPT duplication carriers

18. Plasma NfL levels and longitudinal change rates in

19. Comparison of Pittsburgh compound B and florbetapir in cross‐sectional and longitudinal studies

20. Nucleus Basalis of Meynert Stimulation for Lewy Body Dementia: A Phase I Randomized Clinical Trial

21. Primary Progressive Aphasia Associated With GRN Mutations: New Insights Into the Nonamyloid Logopenic Variant

22. Correction: Clinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairment

23. Plasma NfL levels and longitudinal change rates in C9orf72 and GRN-associated diseases: from tailored references to clinical applications

24. Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes

25. Overview of dominantly inherited AD and top‐line DIAN‐TU results of solanezumab and gantenerumab

26. Phenotypes associated with MAPT duplications

27. Solanezumab in‐depth outcomes

28. Clinical, neuropathological, and genetic characterization of STUB1 variants in cerebellar ataxias: a frequent cause of predominant cognitive impairment

29. Primary Progressive Aphasia Associated With

30. Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis

31. Plasma progranulin levels for frontotemporal dementia in clinical practice: a 10-year French experience

32. Neurobiol Aging

33. Cognitive inhibition impairments in presymptomatic

34. Relevance of Follow-Up in Patients with Core Clinical Criteria for Alzheimer Disease and Normal CSF Biomarkers

35. Biallelic Loss of Function of SORL1 in an Early Onset Alzheimer’s Disease Patient

36. Low Prevalence and Clinical Effect of Vascular Risk Factors in Early-Onset Alzheimer’s Disease

37. A panel study on patients with dominant cerebellar ataxia highlights the frequency of channelopathies

38. Les biomarqueurs du liquide cérébro-spinal dans la maladie d’Alzheimer : un outil de recherche utile dans la pratique clinique courante des consultations mémoire pour les cas complexes

39. Causative Mutations and Genetic Risk Factors in Sporadic Early Onset Alzheimer’s Disease Before 51 Years

40. How many patients are eligible for disease-modifying treatment in Alzheimer’s disease? A French national observational study over 5 years

41. Neurite density is reduced in the presymptomatic phase of C9orf72 disease

42. What is the clinical impact of cerebrospinal fluid biomarkers on final diagnosis and management in patients with mild cognitive impairment in clinical practice? Results from a nation-wide prospective survey in France

43. A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer’s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

44. Integrative system biology analyses of CRISPR-edited iPSC-derived neurons and human brains reveal deficiencies of presynaptic signaling in FTLD and PSP

45. Familial intracranial aneurysm, the relationship of the aortic diameter

46. New practical definitions for the diagnosis of autosomal recessive spastic ataxia of Charlevoix-Saguenay

47. Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia: An MRI Study of 16 French Cases

48. Somatic variants in autosomal dominant genes are a rare cause of sporadic Alzheimer's disease

49. Plasma amyloid levels within the Alzheimer's process and correlations with central biomarkers

50. Neurite density is reduced in the presymptomatic phase of

Catalog

Books, media, physical & digital resources